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Classical vaccination approaches that rely on killed, attenuated or subunit preparations have failed in 
the case of HIV-AIDS. For numerous vaccines that have proven effective against other viral 
diseases, the primary correlate of protection is the generation of broadly neutralizing antibodies 
(BnAbs). Many researchers believe that if a highly effective HIV vaccine is ever achieved, it too will 
be one that generates long lasting humoral immunity in the form of BnAbs (Makedonas and Betts, 
2011). Unfortunately, HIV poses many difficulties for this goal, including the masking of HIV 
envelope protein epitopes by glycans, the conformational flexibility of the HIV envelope, the 
inaccessibility of many conserved epitopes, the diversion of B-cell responses by non-neutralizing 
epitopes, and in some cases, the mimicry of host antigens by the HIV epitopes that happen to be 
both conserved and accessible (Haynes et al., 2012). 
In addition to humoral immunity, however, it is widely recognized that a cellular immune response 
involving cytotoxic CD8
+
 T-cells (CTL; see panel a of the accompanying figure) also plays a critical 
role in controlling HIV replication and disease progression (Makedonas and Betts, 2011). For 
instance, strong, polyfunctional CTL responses (i.e., those involving robust CD8
+
T-cells that produce 
more than one cytokine) characterize the so-called 'elite controllers', the tiny fraction of HIV-infected 
individuals who maintain undetectable viral loads indefinitely and remain disease-free without 
antiretroviral therapy (Ferrando-Martínez et al., 2012). Consequently, T-cell-based vaccine 
strategies, as well as combination strategies designed to induce both humoral and T-cell responses, 
are receiving serious consideration in HIV vaccine research. In a recent study led by Drs. Adel 
Benlahrech and Steven Patterson of the Imperial College School of Medicine in London, researchers 
employed a model vaccine based on structural (Gag) proteins of the simian immunodeficiency virus 
(SIV) to investigate two approaches for potentially broadening the CTL response to vaccination. 
Among the co-authors of this study were Drs. Steven Self and Fuscheng Li, representing the 
Vaccine and Infectious Disease Division and the Public Health Sciences Division of the Fred 
Hutchinson Cancer Research Center. 
CTL target and destroy virally-infected cells by recognizing virus-encoded peptides bound to major 
histocompatibility complex (MHC) class I molecules on the surface of nucleated cells. The peptides  
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that are presented in this way are primarily generated by proteasomal degradation of proteins 
expressed by the target cell. However, the CTL that come to dominate any immune response to viral 
infection recognize a very small proportion of all peptides encoded in a viral genome. This 
immunodominance by certain CTL is strongly influenced by (i) the outcome of proteolytic processing 
in antigen presenting cells (APC) such as dendritic cells (DC), (ii) variation among peptides in affinity 
for MHC class I molecules, (iii) competition in the endoplasmic reticulum among different peptides 
for binding to MHC class I molecules and (iv) additional competition among different CTL for access 
to cognate epitopes on the surface of DC and other APC. These factors are, therefore, key to the 
development of T-cell-based HIV vaccines, because a broad CTL response is needed to reduce the 
likelihood that HIV can escape cellular immunity via mutation. 
To broaden the CTL response, Benlahrech et al. took two approaches. In the first, they fused the 
entire Gag protein to ubiquitin, a small regulatory protein which tags other proteins for proteasomal 
degradation. In their second approach, which focused on reducing both antigenic competition for 
binding to MHC class I molecules and antigenic competition on the surface of DC, the authors split 
the Gag protein into seven, 69-92 amino acid fragments and fused each one to ubiquitin. For 
reference, the authors also investigated full-length unmodified SIV-Gag. In all three cases, the 
corresponding genes (or mini-gene fragments) were cloned into a replication-defective adenovirus 
type 5 (Ad5) vaccine vector. The constructs were then tested using an in vitrohuman priming system 
(described in panel b of the figure). During the experiment, the researchers measured the breadth of 
the CTL response using the enzyme-linked immunosorbent spot (ELISPOT) assay, and they 
evaluated cytokine production and the memory phenotype of T-cells by intracellular cytokine staining 
and flow cytometry. 
Benlahrech et al. found that, overall, most of the CTL responses were directed against the Ad5 
vector. The authors confirmed that fusion of ubiquitin to full-length Gag achieved the desired 
proteasomal targeting, yet this construct resulted in a reduction in the number of epitopes 
recognized by CTL compared to full-length, unmodified Gag. In contrast, the authors found that two 
to six times as many epitopes were recognized in the ubiquitin-fused Gag fragments compared to 
ubiquitin-fused full-length Gag. Fragmentation and ubiquitination had no effect on T-cell memory 
differentiation and polyfunctionality. In this novel investigation of combined ubiquitination and protein 
fragmentation using a human experimental system rather than a mouse model, Benlahrech et 
al. provide encouraging evidence that protein fragmentation may be a worthwhile strategy for 
improving the breadth of T-cell-based HIV vaccines. However, because linking ubiquitin to full-length 
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Gag substantially reduced the breadth of the CTL response, follow-up work is now being conducted 
by the authors to test T-cell responses to Gag protein fragments that are not fused to ubiquitin. 
Based on the known effects of different MHC class I alleles on the immunodominance hierarchy with 
respect to HIV-1, Drs. Li and Self have designed an ingenious strategy in which all unfused Gag 
segments contain the same number of potential epitopes and are, therefore, allowed to vary in 
length. According to Dr. Patterson, preliminary results of this follow-up experiment look promising 
and may provide powerful confirmation that gene fragmentation improves the breadth of T-cell 
responses. 
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Panel a from the Electron Microscopy 
Facility at The National Cancer Institute 
(image downloaded from Wikimedia 
Commons); panel b modified from Figure 
S1 in the open-access publication of 
Benlahrech et al. (2012). 
(a) Scanning electron micrograph of a T-cell 
(right), next to a platelet (center) and red 
blood cell (left). (b) In vitro protocol for the 
generation of SIV-specific memory T-cells. 
Dendritic cells (DC) were generated by 
culturing human monocytes with two 
cytokines, GM-CSF and IL-4, for 7 days. DC 
were then transduced with Ad5 vectors 
expressing SIV-Gag genes for 24 hours. 
Next, the DC were matured with bacterial 
lipopolysaccharide (LPS) and interferon-
gamma (IFN-gamma) for an additional 24 
hours. DC were subsequently co-cultured 
with autologous naive T-cells for 7 days, 
and they were boosted on a weekly basis 
with Ad5-transduced mature DC. 
Intracellular cytokine staining (ICS) was 
performed one day after each boost. 
ELISPOT assays were performed 23 days 
after initial T-cell priming, following a 
resting period of at least 48 hours in 
cytokine-free medium. 
